FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of biochemistry, in particular to antibodies against human angiopoietin-2, coding them nucleic acids and host cells. An antibody is characterised by the fact that it does not bind with human angiopoietin-1. Also claimed is a pharmaceutical composition, which contains the antibody against human angiopoietin-2, intended for cancer treatment, prevention of metastases or treatment of vascular diseases.
EFFECT: invention makes it possible to increase specificity, reduce toxicity and improve pharmacokinetic properties of antibodies against human angiopoietin-2.
13 cl, 13 dwg, 10 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569461C2 |
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2009 |
|
RU2542382C2 |
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2014 |
|
RU2640253C2 |
BISPECIFIC BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2011 |
|
RU2597973C2 |
BISPECIFIC ANTIGEN-BINDING PROTEINS | 2010 |
|
RU2573914C2 |
ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
TRI- OR TETRASPECIFIC ANTIBODIES | 2010 |
|
RU2570633C2 |
BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
NEW ANTI-HUMAN TIE-2 ANTIBODY | 2015 |
|
RU2702553C2 |
ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617971C2 |
Authors
Dates
2015-11-20—Published
2009-12-14—Filed